E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Infectious Endocarditis |
Infektiøs endokarditis |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation of the inner tissue of the heart, such as its valves, caused by infectious agents. |
Infektiøs endokarditis er en tilstand hvor hjerteklapper og/eller omkringliggende væv er inficeret med en bakterie. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000667 |
E.1.2 | Term | Acute and subacute infective endocarditis in diseases classified elsewhere |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate if Benzylpenicillin and Diclocil, given as continuous infusion to patients with infectious endocarditis, leads to a bigger decline in C-reactive protein after 7 days of treatment, compared to Benzylpenicillin and Diclocil given as intermittent infusions to patients with infectious endocarditis. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of Benzylpenicillin and Diclocil, given as continuous infusion to patients with infectious endocarditis, on the following: • Decline in White blood cell count • Drop in body temperature • The concentration of antibiotics in blood plasma and comparison of this concentration to the Minimal Inhibitory Concentration (MIC). • The time the concentration of the given antibiotic remains above the MIC (in short, the T > MIC) • Side effects and complications due to the treatment. • Persisting blood stream infection during the first 3 days of treatment. • The size of valve vegetations at the start and at the end of the trial, examined by ultrasound. • The number of silent cerebral embolisms, valve oedema and valve destruction, at the start and at the end of the trial, examined by magnetic resonance.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Verified infectious endocarditis, with bacteria in the blood, susceptible for either Benzylpenicillin or Diclocil. 2. Less than 96 hours since the onset of intra venous antibiotic treatment. 3. Use of contraception (for fertile women) |
|
E.4 | Principal exclusion criteria |
1. Negative blood cultures. 2. More than 96 hours since the onset of intra venous antibiotic treatment. 3. Planned valve surgery. 4. Planned extraction of a pace maker. 5. Allergy to Benzylpenicillin or Diclocil. 6. Unability to understand information about the study and to give informed consent. 7. Age under 18. 8. Preagnancy. 9. Breastfeeding. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The decline in C-reactive protine, given in percentage, 7 days after the start of the trial. This will be compared between the patientes who recieve intermittent infusion and the patients who recieve continuous infusion. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Potentially differences between the patients who recieve intermittent infusion, and the patientes who recieve continuous infusion, regarding: 1. Decline in white blood cell count. 2. Drop in body temperature. 3. The concentration of antibiotics in blood plasma and comparison of this concentration to the Minimal Inhibitory Concentration (MIC). 4. The time the concentration of the given antibiotic remains above the MIC (in short, the T > MIC) 5. Side effects and complications due to the treatment. 6. Persisting blood stream infection during the first 3 days of treatment. 7. The size of valve vegetations at the start and at the end of the trial, examined by ultrasound. 8. The number of silent cerebral embolisms, valve oedema and valve destruction, at the start and at the end of the trial, examined by magnetic resonance.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Same medicinal product, just given to the patient in a different way. |
|
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last day of treatment for the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |